Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in cancer: A meta-analysis

Gene

Volumn 499, Issue 2, 2012, Pages 237-242

  Jing, Jing Jing ^a   Li, Min ^a   Yuan, Yuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cancer risk; Meta analysis; Polymorphism; TLR4

Indexed keywords

TOLL LIKE RECEPTOR 4;

ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CLINICAL ASSESSMENT; COLORECTAL CANCER; COMPARATIVE STUDY; DIGESTIVE SYSTEM CANCER; ENDOMETRIUM CANCER; GALLBLADDER CANCER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; LYMPHOMA; MELANOMA; META ANALYSIS; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; UTERINE CERVIX CANCER;

AMINO ACID SUBSTITUTION; GASTROINTESTINAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC; TOLL-LIKE RECEPTOR 4;

NEGIBACTERIA;

EID: 84860244687     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.03.045     Document Type: Article

References (42)

1. Agnese D.M., Calvano J.E., Hahm S.J., Coyle S.M., Corbett S.A., Calvano S.E., et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk gram-negative infections. J. Infect. Dis. 2002, 186:1522-1525.
2. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499-511.
3. Akira S., Takeda K., Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001, 2:675-680.
4. Arbour N.C., Lorenz E., Schutte B.C., Zabner J., Kline J.N., Jones M., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 2000, 25:187-191.
5. Ashton K.A., Proietto A., Otton G., Symonds I., McEvoy M., Attia J., et al. Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk. BMC Cancer 2010, 10:382.
6. Balistreri C.R., Caruso C., Carruba G., Miceli V., Campisi I., ListI F., et al. A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications. Curr. Pharm. Des. 2010, 16:718-724.
7. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
8. Boraska Jelavić T., Barisić M., Drmic Hofman I., Boraska V., Vrdoljak E., Peruzović M., et al. Microsatellite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin. Genet. 2006, 70:156-160.
9. Chen Y.C., Giovannucci E., Lazarus R., Kraft P., Ketkar S., Hunter D.J. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res. 2005, 65:11771-11778.
10. Chen R., Alvero A.B., Silasi D.-A., Mor G. Inflammation, cancer and chemoresistance: taking advantage of the Toll-like receptor signaling pathway. Am. J. Reprod. Immunol. 2007, 57:93-107.
11. Cheng I., Plummer S.J., Casey G., Witte J.S. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2007, 16:352-355.
12. Child N.J., Yang I.A., Pulletz M.C., de Courcy-Golder K., Andrews A.L., Pappachan V.J., et al. Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem. Soc. Trans. 2003, 31:652-653.
13. Egger M., Davey SmithG., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
14. El-Omar E.M., Ng M.T., Hold G.L. Polymorphisms in Toll-like receptor genes and risk of cancer. Oncogene 2008, 27:244-252.
15. Etokebe G.E., Knezević J., Petricević B., Pavelić J., Vrbanec D., Dembić Z. Single-nucleotide polymorphisms in genes encoding toll-like receptor -2, -3, -4, and -9 in case-control study with breast cancer. Genet. Test. Mol. Biomarkers 2009, 13:729-734.
16. Faber J., Meyer C.U., Gemmer C., Russo A., Finn A., Murdoch C., et al. Human toll-like receptor 4 mutations are associated with susceptibility to invasive meningococcal disease in infancy. Pediatr. Infect. Dis. J. 2006, 25:80-81.
17. Forrest M.S., Skibola C.F., Lightfoot T.J., Bracci P.M., Willett E.V., Smith M.T., et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br. J. Haematol. 2006, 134:180-183.
18. Garza-Gonzalez E., Bosques-Padilla F.J., Mendoza-Ibarra S.I., Flores-Gutierrez J.P., Maldonado-Garza H.J., Perez-Perez G.I. Assessment of the Toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8-251 polymorphisms in the risk for the development of distal gastric cancer. BMC Cancer 2007, 7:70.
19. Gast A., Bermejo J.L., Claus R., Brandt A., Weires M., Weber A., et al. Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival. PLoS One 2011, 6:e24370.
20. Hellmig S., Fischbach W., Goebeler-Kolve M.E., Fölsch U.R., Hampe J., Schreiber S. Association study of a functional Toll-like receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Leuk. Lymphoma 2005, 46:869-872.
21. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
22. Hold G.L., Rabkin C.S., Chow W.H., Smith M.G., Gammon M.D., Risch H.A., et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007, 132:905-912.
23. Krieg A.M., Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol. Rev. 2007, 220:251-269.
24. Landi S., Gemignani F., Bottari F., Gioia-Patricola L., Guino E., Cambray M., et al. Polymorphisms within inflammatory genes and colorectal cancer. J. Negat. Results Biomed. 2006, 5:15.
25. Liew F.Y., Xu D., Brint E.K., O'Neill L.A. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 2005, 5:446-458.
26. Lin B.K., Clyne M., Walsh M., Gomez O., Yu W., Gwinn M., et al. Tracking the epidemiology of human genes in the literature: the HuGE Published Literature database. Am. J. Epidemiol. 2006, 164:1-4.
27. Lorenz E., Mira J.P., Frees K.L., Schwartz D.A. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch. Intern. Med. 2002, 162:1028-1032.
28. Nieters A., Beckmann L., Deeg E., Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun. 2006, 7:615-624.
29. Pandey S., Mittal R.D., Srivastava M., Srivastava K., Singh S., Srivastava S., et al. Impact of Toll-like receptors. TLR [2 (-196 to -174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women. Gynecol. Oncol. 2009, 114:501-505.
30. Petitti D.B. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis 1994, Oxford University Press, New York.
31. Pharoah P.D., Dunning A.M., Ponder B.A., Easton D.F. Association studies for finding cancer-susceptibility genetic variants. Nat. Rev. Cancer 2004, 4:850-860.
32. Purdue M.P., Lan Q., Wang S.S., Kricker A., Menashe I., Zheng T.Z., et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009, 30:275-281.
33. Rallabhandi P., Bell J., Boukhvalova M.S., Medvedev A., Lorenz E., Arditi M., et al. Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure and signaling. J. Immunol. 2006, 177:322-332.
34. Rigoli L., Di BellaC., Fedele F., Procopio V., Amorini M., Lo GiudiceG., et al. TLR4 and NOD2/CARD15 genetic polymorphisms and their possible role in gastric carcinogenesis. Anticancer. Res. 2010, 30:513-517.
35. Santini D., Angeletti S., Ruzzo A., Dicuonzo G., Galluzzo S., Vincenzi B., et al. Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin. Exp. Immunol. 2008, 154:360-364.
36. Schröder N.W., Schumann R.R. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect. Dis. 2005, 5:156-164.
37. Srivastava K., Srivastava A., Kumar A., Mittal B. Significant association between toll-like receptor gene polymorphisms and gallbladder cancer. Liver Int. 2010, 30:1067-1072.
38. Trejo-de la O.A., Torres J., Pérez-Rodríguez M., Camorlinga-Ponce M., Luna L.F., Abdo-Francis J.M., et al. TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases. Clin. Immunol. 2008, 129:333-340.
39. Türe-Ozdemir F., Gazouli M., Tzivras M., Panagos C., Bovaretos N., Petraki K., et al. Association of polymorphisms of NOD2, TLR4 and CD14 genes with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Anticancer. Res. 2008, 28:3697-3700.
40. Wang R.F., Miyahara Y., Wang H.Y. Toll-like receptors and immune regulation: implications for cancer therapy. Oncogene 2008, 27:181-189.
41. Wang M.H., Helzlsouer K.J., Smith M.W., Hoffman-Bolton J.A., Clipp S.L., Grinberg V., et al. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 2009, 69:874-885.
42. Zheng S.L., Augustsson-Bälter K., Chang B., Hedelin M., Li L., Adami H.O., et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res. 2004, 64:2918-2922.